Please login to the form below

Not currently logged in
Email:
Password:

Shire divests non-core products for USD 213m

Shire agrees to sell a portfolio of non-core products to Spanish-headquartered Almirall Prodesfarma for USD 213m in cash

UK-based pharmaceutical company Shire Pharmaceuticals has agreed to sell a portfolio of non-core products to Spanish-headquartered Almirall Prodesfarma for USD 213m in cash.

The transaction is subject to competition clearances and other customary consents. Shire was advised by Rothschild.

Almirall will gain sunlight skin lesion treatment Solaraze, as well as Vaniqa, a cream used on female facial hair. Six non-promoted products, which are sold in the UK, France, Germany, Italy, Spain and Ireland, are also bundled in with the deal.

The six other products include Lodine (etodolac) for treatment of rheumatoid arthritis and osteoarthritis, Colazide (balsalazide) for treatment of mild to active ulcerative colitis, Meptid (meptazinol) for treatment of pain, and Cebutid (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis.

Shire said the core focus of the firm was to build its attention deficit hyperactivity disorder (ADHD), human genetic therapies, gastrointestinal and renal diseases businesses.

Shire will expand its ADHD expertise to markets outside the US within the next two years, with an initial focus on the EU.

The company concluded that with its recent in-licensing of Juvista, an experimental treatment for scarring, from UK-based Renovo, it will build a new specialty area of regenerative medicine.

Shire's CEO, Matthew Emmens, said: "Our strategic focus is clear and our emphasis in the international markets is on developing competitive positions for our global products that meet the needs of the specialist physicians and their patients, in our chosen areas of expertise."

Almirall's CEO, Dr Jorge Gallardo, added: "We are very satisfied with this acquisition since it expands our international presence in a critical market like the UK and reinforces our position as one of the key European specialty pharmaceutical companies".

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics